Literature DB >> 18240175

Results of treatment of patients with superficial facial rhabdomyosarcomas on protocols of the Intergroup Rhabdomyosarcoma Study Group (IRSG), 1984-1997.

R Beverly Raney1, Murali Chintagumpala, James Anderson, Alberto Pappo, Stephen Qualman, Moody Wharam, Eugene Wiener, William Meyer.   

Abstract

PURPOSE: We analyzed the outcome of 47 patients with superficial facial rhabdomyosarcoma (RMS) treated on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols-III, -IV-Pilot, and -IV.
METHODS: We reviewed patients' records. Clinico-pathologic features, treatment, and outcome were examined to identify prognostic factors.
RESULTS: Thirty-two patients were males; 35 patients were 1-9 years old at diagnosis. Tumor sites were buccal/cheek (N = 21), external nasal/nasolabial (N = 12), lip/chin (N = 9), and masseter (N = 5). Patients (46/47) had localized disease: 18 biopsy only (Group III), 17 microscopic residual tumor (Group II), and 11 complete resection without residual tumor (Group I). Eight-year estimated event-free survival (EFS) and overall survival (OAS) rates were 61% and 65%. Patients <12 months old had inferior EFS, 21%, compared to approximately 68% in older patients (P = 0.077). Eight-year EFS rates were 80% for females and 50% for males (P = 0.096). Eight-year EFS rates were 72% in 33 patients without regional lymph-nodal tumor and 39% in 14 patients with regional nodal tumor (P = 0.07). Eight-year EFS rates were 72% for 22 patients with embryonal RMS and 53% for 23 patients with alveolar RMS (P = 0.28). Location of the primary tumor was not significantly related to outcome.
CONCLUSIONS: Patients with superficial facial RMS often have localized, grossly resectable lesions at the time of presentation. Favorable prognostic factors include age >12 months, female gender, embryonal histology, and no lymph-nodal tumor. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2008        PMID: 18240175      PMCID: PMC3357210          DOI: 10.1002/pbc.21447

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  18 in total

1.  Prognostic factors in head and neck rhabdomyosarcoma.

Authors:  James H Simon; Arnold C Paulino; Russell B Smith; John M Buatti
Journal:  Head Neck       Date:  2002-05       Impact factor: 3.147

2.  A feasibility, toxicity, and early response study of etoposide, ifosfamide, and vincristine for the treatment of children with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS) IV pilot study.

Authors:  C Arndt; M Tefft; E Gehan; J Anderson; M Jenson; M Link; S Donaldson; J Breneman; E Wiener; B Webber; H Maurer
Journal:  J Pediatr Hematol Oncol       Date:  1997 Mar-Apr       Impact factor: 1.289

3.  Treatment of localized nonorbital, nonparameningeal head and neck rhabdomyosarcoma: lessons learned from intergroup rhabdomyosarcoma studies III and IV.

Authors:  Alberto S Pappo; Jane L Meza; Sarah S Donaldson; Moody D Wharam; Eugene S Wiener; Stephen J Qualman; Harold M Maurer; William M Crist
Journal:  J Clin Oncol       Date:  2003-02-15       Impact factor: 44.544

4.  Soft tissue sarcoma of the head and neck in childhood: nonorbital and nonparameningeal sites. A report of the Intergroup Rhabdomyosarcoma Study (IRS)-I.

Authors:  M D Wharam; M A Foulkes; W Lawrence; R D Lindberg; H M Maurer; W A Newton; A H Ragab; R B Raney; M Tefft
Journal:  Cancer       Date:  1984-02-15       Impact factor: 6.860

5.  Intensive chemotherapy including cisplatin with or without etoposide for children with soft-tissue sarcomas.

Authors:  W M Crist; R B Raney; A Ragab; R Heyn; M Wharam; B Webber; J Johnston; M Beltangady
Journal:  Med Pediatr Oncol       Date:  1987

6.  Pediatric orofacial and laryngopharyngeal rhabdomyosarcoma. An Intergroup Rhabdomyosarcoma Study report.

Authors:  M D Wharam; M S Beltangady; R M Heyn; W Lawrence; R B Raney; F B Ruymann; E H Soule; M Tefft; H M Maurer
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1987-11

7.  Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor support evaluating toxicity and response.

Authors:  F B Ruymann; T Vietti; E Gehan; E Wiener; M Wharam; W A Newton; H Maurer
Journal:  J Pediatr Hematol Oncol       Date:  1995-11       Impact factor: 1.289

8.  Soft tissue sarcoma of the head and neck in children and adolescents.

Authors:  A T Lyos; H Goepfert; M A Luna; N Jaffe; A Malpica
Journal:  Cancer       Date:  1996-01-01       Impact factor: 6.860

9.  The Third Intergroup Rhabdomyosarcoma Study.

Authors:  W Crist; E A Gehan; A H Ragab; P S Dickman; S S Donaldson; C Fryer; D Hammond; D M Hays; J Herrmann; R Heyn
Journal:  J Clin Oncol       Date:  1995-03       Impact factor: 44.544

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more
  2 in total

1.  Sinonasal Tract Alveolar Rhabdomyosarcoma in Adults: A Clinicopathologic and Immunophenotypic Study of Fifty-Two Cases with Emphasis on Epithelial Immunoreactivity.

Authors:  Lester D R Thompson; Vickie Y Jo; Abbas Agaimy; Antonio Llombart-Bosch; Gema Nieto Morales; Isidro Machado; Uta Flucke; Paul E Wakely; Markku Miettinen; Justin A Bishop
Journal:  Head Neck Pathol       Date:  2017-09-05

2.  Rare adult masseteric rhabdomyosarcoma and a review of the literature.

Authors:  T Franco; A La Boria; R Domanico; G L Piazzetta; G Donato; E Allegra
Journal:  Case Rep Oncol       Date:  2013-09-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.